Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects

Houston-based Law Firm Offers Assistance, Information to People Affected by Dangerous Tysabri Effects.

Houston, TX (PRWEB) August 2, 2008 -- Tysabri side effects lawyers Pulaski & Middleman announce the launch of a website (http://www.tysabrilawsuitattorney.com) dedicated to assisting people who are suffering serious side effects as a result of taking Tysabri (natalizumab).

Tysabri, a drug used to treat multiple sclerosis (MS) and Crohn's disease, is marketed by Irish drug company Elan and US biotechnology firm Biogen Idec.

In 2005, Tysabri was briefly pulled out of the market after three patients participating in clinical trials contracted progressive multifocal leukoencephalopathy (PML), a rare but deadly viral brain infection. Although the drug was eventually re-released, two more cases of PML were reported in mid-2008, raising more concerns about Tysabri's safety and side effects.

The U.S. Food and Drug Administration (FDA) has also warned that Tysabri has the potential to cause serious liver damage leading to death or the need for a liver transplant.

As experienced litigators, Tysabri lawyers (http://www.tysabrilawsuitattorney.com) Pulaski & Middleman stand ready to assist people who have been adversely affected by this potentially dangerous drug.

About Pulaski & Middleman:

A Houston-based law firm, Pulaski & Middleman has successfully resolved thousands of cases and helped countless clients during its 15-year history. They pride themselves in a personal approach to even the most complicated cases, including medical malpractice, product liability, and other areas of personal injury law.

If you or someone you love is suffering from the side effects of Tysabri, contact Pulaski & Middleman at http://www.tysabrilawsuitattorney.com and discuss your case with a Tysabri attorney today.

###


Contact Information
Adam Pulaski
Pulaski & Middleman
http://www.tysabrilawsuitattorney.com
800-223-3784

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy